EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Insights into Endothelin Receptors in Pulmonary Hypertension

Ruiqi Liu, Tianyi Yuan, Ranran Wang iD, Difei Gong iD, Shoubao Wang, Guanhua Du, Lianhua Fang

International Journal of Molecular Sciences · 16.06.2023 · 24 (12) · 10206

DOI: 10.3390/ijms241210206 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.06.2023. Verfasst von Ruiqi Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and…. Hauptthemen laut MEDLINE: Hypertension, Pulmonary. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary hypertension (PH) is a disease which affects the cardiopulmonary system; it is defined as a mean pulmonary artery pressure (mPAP) > 20 mmHg as measured by right heart catheterization at rest, and is caused by complex and diverse mechanisms. In response to stimuli such as hypoxia and ischemia, the expression and synthesis of endothelin (ET) increase, leading to the activation of various signaling pathways downstream of it and producing effects such as the induction of abnormal vascular proliferation during the development of the disease. This paper reviews the regulation of endothelin receptors and their pathways in normal physiological processes and disease processes, and describes the mechanistic roles of ET receptor antagonists that are currently approved and used in clinical studies. Current clinical researches on ET are focused on the development of multi-target combinations and novel delivery methods to improve efficacy and patient compliance while reducing side effects. In this review, future research directions and trends of ET targets are described, including monotherapy and precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PulmonaryHumansReceptors, EndothelinEndothelin Receptor AntagonistsLungEndothelinsEndothelin-1

Stichwörter der Autor:innen

antagonistdrug targetendothelin receptorpulmonary hypertension

Substanzen

Receptors, EndothelinEndothelin Receptor AntagonistsEndothelinsEndothelin-1

Autor:innen und Institutionen

  • State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
  • Beijing Key Laboratory of Drug Targets Identification and Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.

ORCID-Profile: Ranran Wang, Difei Gong

Förderung

  • National Natural Science Foundation of China
  • CAMS Innovation Fund for Medical Sciences

Zitieren

APA

Liu, R., Yuan, T., Wang, R., Gong, D., Wang, S., Du, G., & Fang, L. (2023). Insights into Endothelin Receptors in Pulmonary Hypertension. International Journal of Molecular Sciences, 24(12), 10206. https://doi.org/10.3390/ijms241210206

Vancouver

Liu R, Yuan T, Wang R, Gong D, Wang S, Du G, et al. Insights into Endothelin Receptors in Pulmonary Hypertension. International Journal of Molecular Sciences. 2023;24(12):10206. doi:10.3390/ijms241210206

BibTeX
@article{Liu2023,
  author = {Liu, Ruiqi and Yuan, Tianyi and Wang, Ranran and Gong, Difei and Wang, Shoubao and Du, Guanhua and Fang, Lianhua},
  title = {Insights into Endothelin Receptors in Pulmonary Hypertension},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {12},
  pages = {10206},
  doi = {10.3390/ijms241210206}
}
Kostenlos starten →